Wednesday, February 23, 2022

February 23, 2022 at 09:02PM HepaGam B

Product approval information is indicated for
•The prevention of Hepatitis B recurrence following liver transplantation in HBsAg-positive liver transplant patients. Also indicated for the treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection.
•Treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/i0Rk1QE

No comments:

Post a Comment